References
- Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastrooesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-697. https://doi.org/10.1016/S0140-6736(10)61121-X
- National Cancer Institute. SEER Cancer Statistics Review, 1975-2006 [Internet]. Bethesda (MD): National Cancer Institute; 2009 [cited 2010 Mar 5]. Available from: http://www. joplink.net/prev/201003/ref/16-001.html.
- Jørgensen JT, Hersom M. HER2 as a Prognostic marker in gastric cancer: a systematic analysis of data from the literature. J Cancer 2012;3:137-144. https://doi.org/10.7150/jca.4090
- Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471-1474. https://doi.org/10.1245/s10434-010-0985-4
- Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature 1984;312:513-516. https://doi.org/10.1038/312513a0
- Sakai K, Mori S, Kawamoto T, Taniguchi S, Kobori O, Morioka Y, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric carcinomas. J Natl Cancer Inst 1986;77:1047-1052.
- Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, et al. HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol 2013;24:2360-2364. https://doi.org/10.1093/annonc/mdt232
- Moelans CB, Milne AN, Morsink FH, Offerhaus GJ, van Diest PJ. Low frequency of HER2 amplification and overexpression in early onset gastric cancer. Cell Oncol (Dordr) 2011;34:89-95.
- Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997;88:323-331. https://doi.org/10.1016/S0092-8674(00)81871-1
- Oren M. Lonely no more: p53 finds its kin in a tumor suppressor haven. Cell 1997;90:829-832. https://doi.org/10.1016/S0092-8674(00)80347-5
- Kim MA, Jung EJ, Lee HS, Lee HE, Jeon YK, Yang HK, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol 2007;38:1386-1393. https://doi.org/10.1016/j.humpath.2007.02.005
- Marx AH, Tharun L, Muth J, Dancau AM, Simon R, Yekebas E, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol 2009;40:769-777. https://doi.org/10.1016/j.humpath.2008.11.014
- Kunz PL, Mojtahed A, Fisher GA, Ford JM, Chang DT, Balise RR, et al. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol 2012;20:13-24. https://doi.org/10.1097/PAI.0b013e31821c821c
- Yan B, Yau EX, Bte Omar SS, Ong CW, Pang B, Yeoh KG, et al. A study of HER2 gene amplification and protein expression in gastric cancer. J Clin Pathol 2010;63:839-842. https://doi.org/10.1136/jcp.2010.076570
- Im SA, Kim JW, Kim JS, Kim MA, Jordan B, Pickl M, et al. Clinicopathologic characteristics of patients with stage III/IV (M(0)) advanced gastric cancer, according to HER2 status assessed by immunohistochemistry and fluorescence in situ hybridization. Diagn Mol Pathol 2011;20:94-100. https://doi.org/10.1097/PDM.0b013e3181fc02b7
- Boers JE, Meeuwissen H, Methorst N. HER2 status in gastrooesophageal adenocarcinomas assessed by two rabbit monoclonal antibodies (SP3 and 4B5) and two in situ hybridization methods (FISH and SISH). Histopathology 2011;58:383-394. https://doi.org/10.1111/j.1365-2559.2011.03760.x
- Toikkanen S, Helin H, Isola J, Joensuu H. Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30- year follow-up. J Clin Oncol 1992;10:1044-1048. https://doi.org/10.1200/JCO.1992.10.7.1044
- Seshadri R, Horsfall DJ, Firgaira F, McCaul K, Setlur V, Chalmers AH, et al. The relative prognostic significance of total cathepsin D and HER-2/neu oncogene amplification in breast cancer. The South Australian Breast Cancer Study Group. Int J Cancer 1994;56:61-65.
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, Mc-Guire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177-182. https://doi.org/10.1126/science.3798106
- Nakajima M, Sawada H, Yamada Y, Watanabe A, Tatsumi M, Yamashita J, et al. The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas. Cancer 1999;85:1894-1902. https://doi.org/10.1002/(SICI)1097-0142(19990501)85:9<1894::AID-CNCR3>3.0.CO;2-J
- Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest 2001;19:554-568. https://doi.org/10.1081/CNV-100103852
- Latif Z, Watters AD, Bartlett JM, Underwood MA, Aitchison M. Gene amplification and overexpression of HER2 in renal cell carcinoma. BJU Int 2002;89:5-9. https://doi.org/10.1046/j.1464-410X.2002.02526.x
- Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 2005;16:273-278. https://doi.org/10.1093/annonc/mdi064
- Hede K. Gastric cancer: trastuzumab trial results spur search for other targets. J Natl Cancer Inst 2009;101:1306-1307. https://doi.org/10.1093/jnci/djp341
Cited by
- Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101) vol.19, pp.None, 2014, https://doi.org/10.1007/s10120-015-0518-8
- Clinical utility of HER2 assessed by immunohistochemistry in patients undergoing curative resection for gastric cancer vol.9, pp.None, 2014, https://doi.org/10.2147/ott.s100979
- Clinicopathological factors associated with HER2-positive gastric cancer : A meta-analysis vol.96, pp.44, 2014, https://doi.org/10.1097/md.0000000000008437
- Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer vol.8, pp.14, 2014, https://doi.org/10.18632/oncotarget.14968
- Characterization of potential driver mutations involved in human breast cancer by computational approaches vol.8, pp.30, 2014, https://doi.org/10.18632/oncotarget.17225
- Epidemiologic Study of Human Epidermal Growth Factor Receptor 2 Expression in Advanced/Metastatic Gastric Cancer: an Assessment of Human Epidermal Growth Factor Receptor 2 Status in Tumor Tissue Sampl vol.17, pp.1, 2014, https://doi.org/10.5230/jgc.2017.17.e6
- Human epidermal growth factor receptor 2 expression in gastric cancer patients treated with curative intent gastrectomy vol.13, pp.1, 2014, https://doi.org/10.14216/kjco.17003
- Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer vol.17, pp.None, 2014, https://doi.org/10.1186/s12876-016-0561-x
- The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature vol.15, pp.None, 2014, https://doi.org/10.1186/s12957-017-1132-5
- Incorporation of p-53 mutation status and Ki-67 proliferating index in classifying Her2-neu positive gastric adenocarcinoma vol.13, pp.1, 2014, https://doi.org/10.1080/19932820.2018.1466573
- SOX9 Stem-Cell Factor: Clinical and Functional Relevance in Cancer vol.2019, pp.None, 2014, https://doi.org/10.1155/2019/6754040
- Obtaining and characterization of monoclonal antibodies against recombinant extracellular domain of human epidermal growth factor receptor 2 vol.26, pp.2, 2014, https://doi.org/10.3233/hab-170327
- Overexpression of HER2/Neu in gastric adenocarcinoma and its correlation with clinicopathological parameters vol.10, pp.4, 2014, https://doi.org/10.4103/ccij.ccij_130_20